Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Non-Small Cell Lung Cancer
Clinical trial register · United States · industry-sponsored

Non-Small Cell Lung Cancer Trials in the USA, 2026

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a US site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full US registry across all sponsors runs to over 22,000 recruiting studies alone.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice — all 9118 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 06 Oct 2026, 03:16 UTC
9118
Studies in scope
industry-sponsored, all four open statuses
4945
Recruiting now
open to new participants
2189
Lead sponsors
across recruiting studies
Top states
California 140 Florida 114 Illinois 72 New York 63 Texas 53
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca22 Merck Sharp & Dohme LLC12 AbbVie7 Eli Lilly and Company6 Hoffmann-La Roche6
State
California140 Florida114 Illinois72 New York63 Texas53
All 48 states
Target enrolment
to

Non-Small Cell Lung Cancer trials in the USA

190 of 9118 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
US states
Start
Not yet open
Study of TUB-040 in Participants With Unresectable or Metastatic Nonsquamous Non-small Cell Lung Cancer
NCT07806773NSCLC, Non Small Cell Lung Cancer
DrugTUB-040
Gilead Sciences
Phase 2
80
California, New Jersey
2026-11
Not yet open
Study of Izalontamab Brengitecan (BMS-986507) in Combination With Osimertinib Versus Osimertinib Monotherapy or Osimertinib in Combination With Platinum-based Chemotherapy for EGFRmt Non-small Cell Lung Cancer (IZABRIGHT-Lung02)
NCT07680790Non-Small Cell Lung Cancer
DrugsIza-bren·Osimertinib·Pemetrexed·Cisplatin
Bristol-Myers Squibb
Phase 3
850
California, Colorado, Florida, Hawaii, Illinois, Maryland, Minnesota, Missouri
2026-09-30
Recruiting
A Study to Evaluate the Efficacy and Safety of Divarasib Compared With Investigator's Choice of Immunotherapy or Observation in Participants With Resected Stage II-III KRAS G12C-Positive Non-Small Cell Lung Cancer (NSCLC)
NCT07541170Non-small Cell Lung Cancer
DrugsDivarasib·Opdivo·Nivolumab·Keytruda
Hoffmann-La Roche
Phase 3
400
California, Georgia, Michigan, Nevada, New Mexico
2026-09-30
Not yet open
Phase 1 Study of STRO-006 in Adults With Refractory Solid Tumors That Are Recurrent or Metastatic
NCT07807345Head & Neck Squamous Cell Carcinoma, Non-Small Cell Lung Cancer, Esophageal Cancer, Gastric Cancer
DrugPembrolizumab
Sutro Biopharma, Inc.
Phase 1
285
California, Florida, Massachusetts, Oklahoma, Texas, Virginia
2026-09-14
Not yet open
A Study of IOV-5001 in Adults With Advanced Solid Tumors
NCT07743723Advanced Solid Tumors, Non-Small Cell Lung Cancer, Triple Negative Breast Cancer (TNBC), Colorectal Cancer
Iovance Biotherapeutics, Inc.
Phase 1/2
106
New York
2026-09
Not yet open
SI-B036-ST-101 in Advanced/Metastatic Solid Tumors
NCT07857616Locally Advanced /Metastatic Solid Tumors, Locally Advanced / Metastatic Solid Tumors, Metastatic Solid Cancers, Non Small Cell Lung Cancer
DrugSI-B036
SystImmune Inc.
Phase 1
424
Connecticut, Florida, Oklahoma, Tennessee, Texas
2026-09
Recruiting
Study of Pembrolizumab + Pemetrexed + Platinum Chemotherapy With or Without Zoldonrasib as First Line Treatment in Metastatic Non-squamous RAS G12D-Mutated NSCLC
NCT07777822NSCLC, Non-small Cell Lung Cancer, Non-Small Cell Lung Cancer NSCLC, Non-Squamous Non Small Cell Lung Cancer
DrugsZoldonrasib·Cisplatin/Carboplatin·Pemetrexed·Pembrolizumab
Revolution Medicines, Inc.
Phase 3
430
Florida
2026-08-14
Recruiting
A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Non-Small Cell Lung Cancer
NCT07659782Non-Small Cell Lung Cancer
DrugVS-7375
Verastem, Inc.
Phase 2
105
California, Florida, Georgia, New Jersey, New York, Texas, Virginia
2026-07-22
Recruiting
A Study to Investigate ANS02 in Participants With EGFR Mutation-Positive Non-Small Cell Lung Cancer
NCT07538804Non-Small Cell Lung Cancer
Avistone Biotechnology Co., Ltd.
Phase 1/2
294
Virginia
2026-07-10
Not yet open
A Study of CLSP 5282 in HLA-A*03:01 Positive Adult Patients With Solid Tumors (SENTINEL-101)
NCT07650357Advanced Solid Tumor, Non Small Cell Lung Cancer, Pancreatic Carcinoma, Colorectal Cancer
Clasp Therapeutics, Inc.
Phase 1
140
North Carolina, Pennsylvania, Tennessee, Texas
2026-07
Recruiting
A Clinical Trial of Calderasib (MK-1084) and Durvalumab in People With Non-Small Cell Lung Cancer (MK-1084-015/KANDLELIT-015)
NCT07554339Non-small Cell Lung Cancer
DrugsCalderasib·Durvalumab
Merck Sharp & Dohme LLC
Phase 3
310
Illinois, Nebraska, New York, North Carolina, Virginia
2026-06-18
Recruiting
A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations
NCT07629960Advanced Solid Tumor, Non-Small Cell Lung Cancer, Colorectal Neoplasms, Pancreatic Ductal Adenocarcinoma
Blueprint Medicines Corporation
Phase 1/2
265
Florida, Louisiana, Massachusetts, Michigan, New Jersey, New York, Tennessee, Texas
2026-06-04
Not yet open
A Study to Evaluate ANS014004 in Combination With EGFR-TKI in Non-Small Cell Lung Cancer
NCT07285148Non-Small Cell Lung Cancer, EGFR Mutation, Metastatic Lung Cancer, MET Alteration
DrugsANS014004·Andamertinib·Osimertinib
Beijing Pearl Biotechnology Limited Liability Company
Phase 1/2
253
New York
2026-06
Recruiting
A Phase 1 Study of IM-1617 in Participants With Advanced Cancer
NCT07578571Colorectal Cancer, Non-Small Cell Lung Cancer, Breast Cancer, Esophageal Cancer
Immunome, Inc.
Phase 1
175
Connecticut, Florida, Massachusetts, Texas
2026-05-21
Recruiting
A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014)
NCT07513376Non-small Cell Lung Cancer
DrugsPembrolizumab Formulated with Berahyaluronidase Alfa·Intismeran autogene
Merck Sharp & Dohme LLC
Phase 3
876
California, Colorado, Connecticut, Illinois, Missouri, Montana, Nebraska, Nevada
2026-05-04
Recruiting
A First-in-Human Study of CKD-703 in Advanced Solid Tumors and Non-Small Cell Lung Cancer
NCT07439094Advanced Solid Tumors, Non-Small Cell Lung Cancer
Chong Kun Dang Pharmaceutical
Phase 1/2
140
Ohio
2026-04-16
Recruiting
A Study to Investigate Ubamatamab With and Without Marlotamig (REGN7075) in Adult Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)
NCT07154290Non Small Cell Lung Cancer, Advanced Non Small Cell Lung Cancer, Metastatic Non Small Cell Lung Cancer, Carcinoma Non Small Cell Lung
DrugsMarlotamig·Ubamatamab·Sarilumab
Regeneron Pharmaceuticals
Phase 2
300
Alabama, Arizona, California, Delaware, District of Columbia, Florida, Illinois, Indiana
2026-03-18
Recruiting
Symbiotic-Lung-20: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers
NCT07227298Advanced/Metastatic Non-Small Cell Lung Cancer, Carcinoma, Non-Small Cell Lung, Non-Small Cell Lung Cancer
DrugsSigvotatug vedotin·PF-08634404
Pfizer
Phase 1/2
162
Arkansas, California, Colorado, Florida, New Jersey, New York, Oregon, Texas
2026-01-30
Recruiting
Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations
NCT07195695Non-small Cell Lung Cancer
DrugsZongertinib·Atezolizumab·Durvalumab·Nivolumab
Boehringer Ingelheim
Phase 3
400
California, District of Columbia, Florida, Georgia, Idaho, Illinois, Massachusetts, Nevada
2026-01-16
Recruiting
An External Control Arm Study in Non-Small Cell Lung Cancer
NCT07174388Non Small Cell Lung Cancer
N-Power Medicine
Observational
650
California, Delaware, Illinois, New Mexico, New York, Pennsylvania, Texas
2026-01-07
Recruiting
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
NCT07222566Advanced Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer, Carcinoma, Non-Small-Cell Lung, Carcinoma, Non-Small-Cell Lung (NSCLC)
DrugsPF-08634404·Pembrolizumab
Pfizer
Phase 3
1,410
Arizona, Arkansas, California, Florida, Illinois, Indiana, Louisiana, Maryland
2026-01-06
Recruiting
Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations
NCT07185997Non-Small-Cell Lung Cancer, Metastatic Non-Small-Cell Lung Cancer, Advanced Non-Small-Cell Lung Cancer, EGFR P-Loop and Alpha C-Helix Compressing
DrugFurmonertinib
ArriVent BioPharma, Inc.
Phase 3
480
California, Colorado, Illinois, Michigan, New York, Ohio, Pennsylvania, Texas
2025-12-17
Recruiting
A Phase 1/2 Clinical Trial to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HMBD-501 in Patients With HER3-Expressing Solid Tumors
NCT06956690Melanoma (Skin), Non Small Cell Lung Cancer, Breast Cancer
Hummingbird Bioscience
Phase 1/2
180
California, Indiana, Michigan, Texas
2025-12-17
Recruiting
A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan, Monotherapy or in Combination With Osimertinib, Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer
NCT07155187Non-Small Cell Lung Cancer, c-MET
DrugsTelisotuzumab Adizutecan·Osimertinib
AbbVie
Phase 2/3
490
Arkansas, California, Florida, Indiana, Minnesota, Nebraska, New Hampshire, New Jersey
2025-12-10
Recruiting
A Study of PT0511 in Participants With KRAS Mutated or Amplified Advanced Solid Tumors
NCT07300150Colorectal Cancer, Pancreatic Cancer, Non-Small Cell Lung Cancer, Solid Tumor
DrugCetuximab
PAQ Therapeutics, Inc.
Phase 1
210
Massachusetts, Texas, Utah, Virginia
2025-11-21
By invitation
A Phase 1/1b of RNDO-564 Single Agent or in Combination With Pembrolizumab in Bladder Cancer and Other Solid Tumors Associated With Nectin-4
NCT07218003Non Small Cell Lung Cancer, Cervical Cancer, Head and Neck Squamous Cell Cancer, Triple Negative Breast Cancer (TNBC)
DrugPembrolizumab
Rondo Therapeutics
Phase 1
149
California, Connecticut, Michigan, New York, North Carolina, South Carolina, Tennessee, Texas
2025-11-17
Recruiting
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
NCT07100080Non-Small Cell Lung Cancer
DrugsIza-bren·Pemetrexed·Cisplatin·Carboplatin
Bristol-Myers Squibb
Phase 2/3
500
California, Colorado, Florida, Georgia, Illinois, Massachusetts, Missouri, Nevada
2025-11-05
Recruiting
FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors
NCT07216105Non-Small Cell Lung Cancer, Colorectal Cancer, Breast Cancer, Ovarian Cancer
DrugsTrastuzumab·Cetuximab
Fate Therapeutics
Phase 1
119
California, Minnesota, Pennsylvania, Texas
2025-11-04
Recruiting
Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer
NCT06899126Non-small Cell Lung Cancer
DrugsTrastuzumab deruxtecan·Pemetrexed·Keytruda·Pembrolizumab
Daiichi Sankyo
Phase 3
686
Alaska, California, Florida, Georgia, Hawaii, Illinois, Massachusetts, Minnesota
2025-10-24
Recruiting
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
NCT06793215Non-Small Cell Lung Cancer, KRAS G12C Lung Cancer
DrugsDivarasib·Pemetrexed·Cisplatin·Carboplatin
Hoffmann-La Roche
Phase 3
600
Alaska, Arizona, California, Colorado, Connecticut, Florida, Georgia, Idaho
2025-10-24
Recruiting
A Study of Tolododekin Alfa (ANK-101) in Combination With an Anti-PD-1/PD-L1 Antibody in Participants With Advanced Non-Small Cell Lung Cancer
NCT07027514Non Small Cell Lung Cancer
DrugsTolododekin alfa·Cetrelimab
Ankyra Therapeutics, Inc
Phase 1
60
Florida, Illinois, Indiana, Michigan, Minnesota, New York, North Carolina, Pennsylvania
2025-10-22
Recruiting
A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)
NCT07190248Non-small Cell Lung Cancer
Drugs) Berahyaluronidase alfa·Calderasib·Paraplatin·Pemetrexed
Merck Sharp & Dohme LLC
Phase 3
675
Alabama, Connecticut, Florida, Georgia, Indiana, Maine, New Jersey, New York
2025-10-08
Active, closed
A Phase I Clinical Study to Evaluate the PK Profile, Efficacy, Safety and Immunogenicity of HLX17 vs. Keytruda® in Multiple Resected Solid Tumors
NCT07160335Non-small Cell Lung Cancer, Melanoma, Renal Cell Carcinoma
DrugsUS-sourced Keytruda·Pembrolizumab
Shanghai Henlius Biotech
Phase 1
174
California, Florida, Texas, Washington
2025-09-26
Recruiting
A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer (NSCLC)
NCT07111520Non-small Cell Lung Cancer
DrugsBNT326·Pumitamig
BioNTech SE
Phase 1/2
880
California, Connecticut, District of Columbia, Florida, Massachusetts, Michigan, New York, Ohio
2025-09-22
Active, closed
A Study to Evaluate Two Dosing Regimens of Subcutaneous Nivolumab in Combination With Intravenous Ipilimumab and Chemotherapy in Participants With Previously Untreated Metastatic or Recurrent Non-Small Cell Lung Cancer (NSCLC)
NCT06946797Non-Small Cell Lung Cancer
DrugsNivolumab and rHuPH20·Yervoy·Ipilimumab·Pemetrexed
Bristol-Myers Squibb
Phase 2
76
Alaska, California, Idaho, Ohio, Pennsylvania
2025-09-19
Recruiting
A Study of [225Ac]Ac-AKY-1189 in Patients With Solid Tumors
NCT07020117Urothelial Carcinoma Bladder, Triple Negative Breast Cancer (TNBC), Hormone Receptor Positive Breast Adenocarcinoma, Non Small Cell Lung Cancer
Aktis Oncology, Inc.
Phase 1
150
California, Florida, Iowa, Kansas, Maryland, Michigan, New York, Pennsylvania
2025-08-22
Recruiting
A Study to Assess the Efficacy of WSD0922-FU in Patients With C797S+ Advanced Non-small Cell Lung Cancer
NCT06868485Non Small Cell Lung Cancer
DrugWSD0922-FU
Wayshine Biopharm, Inc.
Phase 2
40
California, Florida, Michigan, New Jersey, Ohio, Pennsylvania, Texas, Virginia
2025-08-18
Recruiting
A Study of Novel Combinations in Non-Small Cell Lung Cancer (NSCLC)
NCT07098338Non-Small Cell Lung Cancer
DrugsRamucirumab·Rilvegostomig·Dato-DXd
AstraZeneca
Phase 2
278
California, Georgia, Maryland, Texas, Virginia
2025-08-07
Recruiting
A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors
NCT07115043Melanoma, Non-small Cell Lung Cancer, Squamous Cell Carcinoma (Skin), Renal Cell Carcinoma
DrugRilvegostomig
AstraZeneca
Phase 1/2
120
Michigan, Missouri, Pennsylvania, Texas, Virginia
2025-07-29
Recruiting
A Study to Find a Suitable Dose of ASP5834 in Adults With Solid Tumors
NCT07094204Solid Tumor, Non-Small-Cell Lung Cancer, Pancreatic Ductal Adenocarcinoma, Colorectal Cancer
DrugPanitumumab
Astellas Pharma Inc
Phase 1
364
California, Georgia, Louisiana, Michigan, Missouri, New Jersey, New York, Ohio
2025-07-25
Recruiting
This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
NCT06758401Non-Small Cell Lung Cancer, Carcinoma, Non-Small-Cell Lung, Carcinoma, Non-Small-Cell Lung (NSCLC)
DrugsSigvotatug vedotin·Pembrolizumab
Pfizer
Phase 3
714
California, Colorado, District of Columbia, Florida, Illinois, Kansas, Maine, Massachusetts
2025-07-23
Recruiting
Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC
NCT06765109Non-small Cell Lung Cancer, Anaplastic Lymphoma Kinase-positive
DrugsNeladalkib·Alectinib
Nuvalent Inc.
Phase 3
450
Arizona, California, Colorado, Florida, Georgia, Massachusetts, Michigan, Missouri
2025-07-17
Recruiting
A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
NCT07020221Pancreatic Ductal Adenocarcinoma, Non Small Cell Lung Cancer, Colorectal Cancer, Solid Tumor, Adult
DrugsVS-7375·Erbitux·Cetuximab·Nab-paclitaxel
Verastem, Inc.
Phase 1/2
295
California, Maryland, Massachusetts, Michigan, Missouri, New York, Pennsylvania, Tennessee
2025-06-24
Recruiting
A Phase II Clinical Study to Evaluate HLX43 in Subjects With Advanced Non-small Cell Lung Cancer (NSCLC)
NCT06907615Non Small Cell Lung Cancer
DrugsHLX43 2·HLX43 1
Shanghai Henlius Biotech
Phase 2
243
Texas
2025-06-09
Recruiting
Prospective External Control Cohort In Patients With Newly Diagnosed Advanced or Metastatic EGFR Mutant Non-Small Cell Lung Cancer
NCT07028489Non Small Cell Lung Cancer
N-Power Medicine
Observational
130
California, Delaware, Idaho, Illinois, New Mexico, Pennsylvania, Texas
2025-06-05
Recruiting
A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas
NCT06999187Triple Negative Breast Cancer, HER2-negative Breast Cancer, Non Small Cell Lung Cancer, Cervical Cancer
Dren Bio
Phase 1
96
Colorado, Florida, North Carolina, Oklahoma, South Carolina, Texas, Virginia
2025-06-03
Recruiting
A Multinational Study Assessing an Oral EGFR Inhibitor, DZD6008 in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN1)
NCT06905197Non Small Cell Lung Cancer
DrugsDZD6008·Sunvozertinib
Dizal Pharmaceuticals
Phase 1
140
New York, Virginia
2025-05-13
Recruiting
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
NCT06881784NSCLC (Non-small Cell Lung Cancer), Non-Small Cell Lung Cancer, NSCLC, NSCLC (Non-small Cell Lung Carcinoma)
DrugsCetuximab·Docetaxel
Revolution Medicines, Inc.
Phase 3
590
Alabama, California, Connecticut, Florida, Georgia, Illinois, Iowa, Kansas
2025-05-06
Recruiting
BBO-11818 in Adult Subjects With KRAS Mutant Cancer
NCT06917079Non-Small Cell Lung Cancer, NSCLC, PDAC - Pancreatic Ductal Adenocarcinoma, CRC (Colorectal Cancer)
DrugsBBO-10203·MFOLFIRINOX·MFOLFOX6·Cetuximab
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
Phase 1
665
California, Connecticut, Florida, Illinois, Massachusetts, New York, Tennessee, Texas
2025-03-31
Recruiting
A Study of Pembrolizumab With or Without Chemotherapy in Combination With Additional Treatments for Advanced Non-Small Cell Lung Cancer (NSCLC) (MK-3475-01G/KEYMAKER U01)
NCT06731907Non-small Cell Lung Cancer
DrugsPatritumab deruxtecan·Abraxane·Paraplatin·Taxol
Merck Sharp & Dohme LLC
Phase 2
90
Kentucky, Maryland, North Dakota, Pennsylvania, South Dakota
2025-03-30
Recruiting
Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
NCT06810544Non Small Cell Lung Cancer, Glioma Glioblastoma Multiforme, Glioma, Malignant, Solid Tumor
DrugAbemaciclib
Tango Therapeutics, Inc.
Phase 1/2
191
Arizona, California, District of Columbia, Florida, Illinois, Massachusetts, Minnesota, New York
2025-03-24
Recruiting
Safety and Preliminary Efficacy of Pumitamig (BNT327), an Investigational Therapy for Patients With Non-small Cell Lung Cancer in Combination With Chemotherapy as First-line or Second-line Treatment
NCT06841055Non-small Cell Lung Cancer
DrugsPumitamig·Docetaxel
BioNTech SE
Phase 2
60
Alabama, Florida, Kentucky, New York, Texas
2025-03-03
Recruiting
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
NCT06767514Non-Small Cell Lung Cancer
DrugsIvonescimab·Pembrolizumab
Summit Therapeutics
Phase 3
780
Arizona, Arkansas, California, Colorado, Florida, Georgia, Illinois, Indiana
2025-02-27
Recruiting
A Phase 1, First-in-human Study of OKN4395 and Pembrolizumab in Patients With Solid Tumors
NCT06789172Solid Tumours, Sarcoma, HNSCC, Non Small Cell Lung Cancer
DrugFamotidine
Epkin
Phase 1
146
California, Texas
2025-01-23
Recruiting
A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
NCT06568939Non-Small Cell Lung Cancer, c-MET
DrugTelisotuzumab vedotin
AbbVie
Phase 2
150
Arizona, Arkansas, California, Connecticut, Florida, Georgia, Hawaii, Illinois
2025-01-20
Recruiting
Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer
NCT06712316Non-small Cell Lung Cancer
DrugsPumitamig·Pemetrexed·Paclitaxel·Carboplatin
BioNTech SE
Phase 2/3
1,580
Alabama, Alaska, California, Colorado, District of Columbia, Florida, Georgia, Indiana
2025-01-07
Active, closed
A Clinical Study of Pembrolizumab (+) Berahyaluronidase Alfa (MK-3475A) to Treat Newly-diagnosed Metastatic Non-small Cell Lung Cancer (MK-3475A-F84)
NCT06698042Lung Cancer, Non-Small Cell Lung Cancer
Drugs) Berahyaluronidase alfa·Keytruda·Pembrolizumab
Merck Sharp & Dohme LLC
Phase 3
67
California, Illinois, New York, Ohio
2024-11-21
Recruiting
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
NCT06692738Non-small Cell Lung Cancer
DrugsRilvegostomig·Nab-paclitaxel·Keytruda·Paclitaxel
AstraZeneca
Phase 3
1,160
Arizona, Arkansas, California, Connecticut, Delaware, Florida, Georgia, Idaho
2024-11-18
Active, closed
A Study of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer Treatments for Adult Patients With Operable Non-Small Cell Lung Cancer (NSCLC)
NCT06465329Non-Small Cell Lung Cancer
DrugsMarlotamig·Cemiplimab
Regeneron Pharmaceuticals
Phase 2
120
California, Illinois, Michigan, Ohio, Oregon, Rhode Island, South Dakota, Tennessee
2024-11-18
Active, closed
A Study of Valemetostat Tosylate Plus Pembrolizumab Versus Pembrolizumab Alone in First-Line NSCLC Without Actionable Genomic Alterations
NCT06644768Non-small Cell Lung Cancer, Lung Cancer
DrugsValemetostat·Valemetostat Tosylate·Keytruda·Pembrolizumab
Daiichi Sankyo
Phase 1/2
137
California, Florida, Kentucky, Minnesota, New York, Pennsylvania, Virginia
2024-10-30
Active, closed
A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
NCT06607185Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer, Colorectal Cancer, Advanced Solid Tumor
Drugs5Fluorouracil·Leucovorin·Cetuximab·Irinotecan
Eli Lilly and Company
Phase 1
750
Alabama, Arizona, California, Connecticut, Illinois, Indiana, Massachusetts, Michigan
2024-10-21
Recruiting
Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers
NCT06562192Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer, HR+/HER2- Ductal and Lobular Breast Cancer, Triple Negative Breast Cancer
Novartis Pharmaceuticals
Phase 1
162
Alabama, California, Florida, Massachusetts, Michigan, Minnesota, Texas, Washington
2024-10-15
Active, closed
A Phase III, Randomised Study of Adjuvant Dato-DXd in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care, Following Complete Tumour Resection, in Participants With Stage I Adenocarcinoma NSCLC Who Are ctDNA-positive or Have High-risk Pathological Features
NCT06564844Non-small Cell Lung Cancer
DrugsRilvegostomig·Dato-DXd·Vinorelbine·Etoposide
AstraZeneca
Phase 3
25
Arizona, California, Colorado, District of Columbia, Florida, Illinois, Kansas, Kentucky
2024-10-15
Recruiting
A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%
NCT06561386Non-small Cell Lung Cancer
DrugsRelatlimab·Pemetrexed·Nivolumab·Cisplatin
Bristol-Myers Squibb
Phase 3
1,000
Alabama, Arizona, California, Colorado, Florida, Idaho, Illinois, Kansas
2024-10-07
Active, closed
A Study Evaluating the Efficacy and Safety of Divarasib Versus Sotorasib or Adagrasib in Participants With Previously Treated KRAS G12C-positive Advanced or Metastatic Non-Small Cell Lung Cancer
NCT06497556Non-Small Cell Lung Cancer, KRAS G12C Lung Cancer
DrugsDivarasib·Adagrasib·Sotorasib
Hoffmann-La Roche
Phase 3
338
Arizona, California, Connecticut, Florida, Illinois, Maine, Massachusetts, Michigan
2024-09-23
Recruiting
A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors
NCT06561685Metastatic Solid Tumor, Advanced Solid Tumor, Non-small Cell Lung Cancer, SMARCA4-Deficient Tumor
DrugsNab-paclitaxel·Pemetrexed·Paclitaxel·Cisplatin
Eli Lilly and Company
Phase 1
340
California, Colorado, Florida, Illinois, Massachusetts, New York, Ohio, Tennessee
2024-09-19
Active, closed
Anvumetostat Alone or in Combination With Other Therapies in Subjects With Advanced Thoracic Tumors With Homozygous MTAP-deletion (Master Protocol) (MTAPESTRY 104).
NCT06333951Thoracic Tumors, Non-small Cell Lung Cancer
DrugsAnvumetostat·Sotorasib·Pemetrexed·Paclitaxel
Amgen
Phase 1
49
California, Colorado, Connecticut, Minnesota, Missouri, Nevada, New York, Oklahoma
2024-09-17
Recruiting
MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors
NCT06586515Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer, Colorectal Cancer
DrugsLeucovorin·Cetuximab·Irinotecan·Adrucil
Eli Lilly and Company
Phase 1
630
California, Colorado, District of Columbia, Florida, Georgia, Indiana, Massachusetts, Michigan
2024-09-12
Active, closed
Volrustomig Priming Regimens Exploratory Phase II Platform Study
NCT06448754Non-small Cell Lung Cancer
DrugsVolrustomig·Ramucirumab·Pemetrexed·Paclitaxel
AstraZeneca
Phase 2
194
California, North Carolina
2024-08-27
Active, closed
A Phase 1, Dose-escalation Study of [225Ac]-FPI-2068 in Adult Patients With Advanced Solid Tumours
NCT06147037Advanced Solid Tumor, Metastatic Colorectal Carcinoma, Head and Neck Squamous Cell Carcinoma, Non-small Cell Lung Cancer
AstraZeneca
Phase 1
13
California, Illinois, Nebraska, Ohio, Texas, Washington
2024-07-31
Recruiting
A Study of the Oral EGFR Inhibitor PLB1004 in Non-Small Cell Lung Cancer
NCT06046495Non-Small Cell Lung Cancer
DrugAndamertinib
Avistone Biotechnology Co., Ltd.
Phase 1
81
California, Kentucky, Nebraska, New York, Tennessee, Washington
2024-07-08
Recruiting
FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC
NCT06303505Ovarian Cancer, Non-small Cell Lung Cancer
DrugTUB-040
Gilead Sciences
Phase 1/2
250
Alabama, Connecticut, Georgia, Kentucky, Massachusetts, New Jersey, New York, Ohio
2024-06-12
Recruiting
Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]
NCT06422143Non-small Cell Lung Cancer, NSCLC
DrugsSacituzumab tirumotecan·Nab-paclitaxel·Keytruda·Paclitaxel
Merck Sharp & Dohme LLC
Phase 3
851
Arkansas, California, Colorado, District of Columbia, Florida, Georgia, Illinois, Michigan
2024-06-10
Recruiting
A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)
NCT06345729Non-small Cell Lung Cancer
DrugsCalderasib·Keytruda·Pembrolizumab
Merck Sharp & Dohme LLC
Phase 3
348
California, Connecticut, Florida, Illinois, Missouri, Montana, New Jersey, New York
2024-05-24
Recruiting
Open-label Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer
NCT06343402Non-small Cell Lung Cancer, Metastatic Non-Small Cell Lung Cancer, NSCLC, KRAS G12C
DrugsBBO-10203·Pembrolizumab
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
Phase 1
350
Alabama, California, Colorado, Connecticut, Illinois, Kansas, Maryland, Michigan
2024-05-22
Recruiting
This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatment With Toripalimab in Patients With Advanced Solid Tumors
NCT06451497Non Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Pancreas Adenocarcinoma, Biliary Tract Cancer
Zumutor Biologics Inc.
Phase 1
100
Massachusetts, Texas
2024-05-22
Recruiting
Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer
NCT06350097Non-small Cell Lung Cancer
DrugsDato-DXd·Osimertinib
AstraZeneca
Phase 3
582
California, Connecticut, District of Columbia, Florida, Hawaii, Illinois, Indiana, Maryland
2024-04-29
Recruiting
Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations
NCT06357533Non-Small Cell Lung Cancer
DrugsRilvegostomig·Dato-DXd·Keytruda·Pembrolizumab
AstraZeneca
Phase 3
675
Alaska, Arizona, Arkansas, California, Florida, Georgia, Illinois, Indiana
2024-04-11
Recruiting
Study to Evaluate Adverse Events, Optimal Dose, and Change in Disease Activity, With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
NCT06236438Non-Small Cell Lung Cancer
DrugsLivmoniplimab·Budigalimab·Pemetrexed·Cisplatin
AbbVie
Phase 2/3
840
California, Florida, Georgia, Illinois, Kansas, Kentucky, Michigan, Missouri
2024-04-10
Recruiting
A Study of IBI363 in Subjects with Advanced Solid Malignancies
NCT06281678Melanoma, Non-small Cell Lung Cancer, Colorectal Cancer, Renal Cell Cancer
DrugLenvatinib
Innovent Biologics (Suzhou) Co. Ltd.
Phase 2
178
California, Florida, Kansas, Michigan, Texas, Washington
2024-04-08
Recruiting
BostonGene and Exigent Genomic INsight Study
NCT06272864Breast Cancer, Non-small Cell Lung Cancer, Melanoma, Sarcoma
BostonGene
Observational
400
Arkansas, California, Indiana, New Mexico, Oklahoma, Texas, Washington
2024-04-08
Recruiting
A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
NCT06312137Non Small Cell Lung Cancer
DrugsSacituzumab tirumotecan·Pemetrexed·Gemcitabine·Paclitaxel
Merck Sharp & Dohme LLC
Phase 3
780
Arkansas, California, Connecticut, Florida, Georgia, Illinois, Indiana, Kentucky
2024-04-03
Recruiting
A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression
NCT06051695Solid Tumor, Adult, Colorectal Cancer, NSCLC, Non Small Cell Lung Cancer
A2 Biotherapeutics Inc.
Phase 1/2
474
Arizona, California, Florida, Minnesota, Missouri, New York, Ohio, Tennessee
2024-04-03
Recruiting
Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors
NCT06218914Non-small Cell Lung Cancer, Colorectal Carcinoma, Pancreatic Ductal Adenocarcinoma, Endometrial Cancer
AstraZeneca
Phase 1
108
California, Florida, Illinois, Kansas, Massachusetts, Missouri, New York, Oregon
2024-03-22
Recruiting
A Phase 1 of CTX-8371 in Patients With Advanced Malignancies
NCT06150664Non Small Cell Lung Cancer, Triple Negative Breast Cancer, Hodgkin Lymphoma, Head and Neck Squamous Cell Carcinoma
Compass Therapeutics
Phase 1
85
Florida, Georgia, Indiana, Massachusetts, New York, Tennessee, Washington
2024-03-19
Active, closed
Phase I Study of Autologous CD8+ and CD4+ Engineered T Cell Receptor T Cells in Subjects With Advanced or Metastatic Solid Tumor
NCT06105021Pancreatic Ductal Adenocarcinoma, Non-Small Cell Lung Cancer, Colorectal Cancer, Solid Tumor
Affini-T Therapeutics, Inc.
Phase 1/2
100
California, Connecticut, New York, Oregon, Tennessee, Texas, Washington, Wisconsin
2024-03-06
Recruiting
A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABSK112 in Patients With Non-Small Cell Lung Cancer
NCT06225804Non-Small Cell Lung Cancer
Abbisko Therapeutics Co, Ltd
Phase 1
164
California
2024-02-22
Active, closed
Study to Assess Neoadjuvant Durvalumab (D) and Platinum-Based Chemotherapy (CT), Followed by Either Surgery and Adjuvant D or CRT and Consolidation D, in Resectable or Borderline Resectable Stage IIB-IIIB NSCLC (MDT-BRIDGE)
NCT05925530Non-small Cell Lung Cancer
DrugDurvalumab
AstraZeneca
Phase 2
142
New York, Texas, Virginia
2024-02-22
Recruiting
A Study to Evaluate the Efficacy and Safety of Sutetinib Maleate Capsule in Locally Advanced or Metastatic NSCLC
NCT06010329Non-small Cell Lung Cancer
DrugSutetinib Maleate
Teligene US
Phase 2
66
California, Florida, Georgia, Iowa, Kentucky, New York, Texas
2023-12-27
Active, closed
A Study of Participant Reported Preference for Subcutaneous Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) Over Intravenous Pembrolizumab (MK-3475) Formulation in Multiple Tumor Types (MK-3475A-F11)
NCT06099782Non-Small Cell Lung Cancer, Renal Cell Carcinoma, Melanoma
Drugs) Berahyaluronidase alfa·Keytruda·Pembrolizumab
Merck Sharp & Dohme LLC
Phase 2
147
Alabama, Alaska, Arkansas, California, Florida, Georgia, Washington
2023-12-26
Active, closed
A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002)
NCT06077760Non-small Cell Lung Cancer
DrugsIntismeran autogene·Keytruda·Pembrolizumab
Merck Sharp & Dohme LLC
Phase 3
868
Alaska, Arizona, California, Colorado, District of Columbia, Florida, Georgia, Idaho
2023-12-06
Recruiting
Test-retest Evaluation of [18F]F-AraG PET
NCT06084806Non-small Cell Lung Cancer
CellSight Technologies, Inc.
Phase 2
10
Iowa
2023-10-31
Recruiting
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients
NCT05899608Non-Small Cell Lung Cancer
DrugsIvonescimab·Pembrolizumab
Summit Therapeutics
Phase 3
1,600
Arizona, Arkansas, California, Colorado, Connecticut, Florida, Georgia, Illinois
2023-10-26
Recruiting
SIBYL: obServation of Therapy Response With lIquid BiopsY evaLuation
NCT05935384Non-small Cell Lung Cancer, Colorectal Cancer, Breast Cancer
Guardant Health, Inc.
Observational
470
Illinois
2023-10-25
Recruiting
First-In-Human Study of STX-721/PFL-721 in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR or HER2 Exon 20 Insertion Mutations
NCT06043817Non-Small Cell Lung Cancer, NSCLC, EGFR/HER2 Exon 20 Insertion Mutation
Pierre Fabre Medicament
Phase 1/2
345
California, North Carolina, Pennsylvania, Tennessee, Texas, Utah, Virginia
2023-09-26
Recruiting
Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
NCT05983432Non Small Cell Lung Cancer, Esophageal Cancer, Small Cell Lung Cancer, Nasopharyngeal Cancer
DrugIza-bren
SystImmune Inc.
Phase 1
540
California, Colorado, Connecticut, District of Columbia, Florida, Illinois, Iowa, Kentucky
2023-08-08
Active, closed
A Trial to Learn How the Combination of Fianlimab With Cemiplimab and Chemotherapy Works Compared With Cemiplimab and Chemotherapy for Treating Adult Patients With Advanced Non-small Cell Lung Cancer
NCT05800015Non-small Cell Lung Cancer
DrugsFianlimab·Cemiplimab·Paraplatin·Pemetrexed
Regeneron Pharmaceuticals
Phase 2/3
160
Arizona, California, Colorado, Connecticut, Florida, Illinois, Louisiana, Mississippi
2023-08-08
Recruiting
A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation
NCT05877599Non-small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Colorectal Carcinoma, Pancreatic Adenocarcinoma
AstraZeneca
Phase 1
45
Arizona, California, Florida, Massachusetts, New Jersey, New York, North Carolina, Oregon
2023-07-12
Active, closed
ONC-392 Versus Docetaxel in Metastatic NSCLC That Progressed on PD-1/PD-L1 Inhibitors
NCT05671510Non Small Cell Lung Cancer
DrugsGotistobart·Taxotere·Docetaxel
OncoC4, Inc.
Phase 3
630
Alabama, Arkansas, California, Connecticut, Florida, Illinois, Indiana, Kansas
2023-06-28
Active, closed
A Screening Study to Collect Samples for TAA, HLA & HLA Loss of Heterozygosity in Patients With Metastatic Solid Tumors
NCT05812027Head and Neck Cancer, Cervical Cancer, Non Small Cell Lung Cancer, HPV16 Related Cancers
TScan Therapeutics, Inc.
Observational
1,150
Arizona, California, Connecticut, Florida, Illinois, Kentucky, Michigan, Minnesota
2023-06-26
Recruiting
TT-4 and TT-10 as Single Agents and in Combination in Subjects With Advanced Selected Solid Tumors and Pleural Mesothelioma
NCT04969315Renal Cell Cancer, Castrate Resistant Prostate Cancer, Non Small Cell Lung Cancer, Pleural Mesothelioma Malignant
Portage Biotech
Phase 1/2
35
California, Texas
2023-06-23
Recruiting
IPH5201 and Durvalumab in Patients With Resectable Non-Small Cell Lung Cancer (MATISSE)
NCT05742607Non Small Cell Lung Cancer
DrugDurvalumab
Innate Pharma
Phase 2
70
Florida, Illinois, New York, Texas, Wisconsin
2023-06-23
Recruiting
A Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib as a Single Agent or in Combination With Other Anti-Cancer Therapies in Participants With Previously Untreated Advanced or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C Mutation
NCT05789082Non-Small Cell Lung Cancer
DrugsDivarasib·Pemetrexed·Cisplatin·Carboplatin
Hoffmann-La Roche
Phase 1/2
320
California, Connecticut, Florida, New York, Texas, Virginia
2023-06-20
Active, closed
Study of TNG260 and an Anti-PD Antibody in STK11 Mutated Solid Tumors
NCT05887492Non Small Cell Lung Cancer, Solid Tumors, Adult, Lung Cancer, Lung Adenocarcinoma
DrugsKeytruda·Pembrolizumab
Tango Therapeutics, Inc.
Phase 1/2
126
California, Colorado, Florida, Massachusetts, Michigan, New York, Tennessee, Texas
2023-06-12
Active, closed
A Study of HFB200603 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid Tumors
NCT05789069Renal Cell Carcinoma, Melanoma, Non Small Cell Lung Cancer, Gastric Cancer
DrugTislelizumab
HiFiBiO Therapeutics
Phase 1
83
California, Pennsylvania, Virginia
2023-05-09
Active, closed
Study of JANX008 in Subjects With Advanced or Metastatic Solid Tumor Malignancies
NCT05783622Non-Small Cell Lung Cancer, Renal Cell Carcinoma, Squamous Cell Carcinoma of the Head and Neck, Colorectal Carcinoma
Janux Therapeutics
Phase 1
130
California, Georgia, Illinois, Michigan, Missouri, New York, North Carolina, Ohio
2023-04-19
Active, closed
A Study of Tislelizumab in Combination With Investigational Agents in Participants With Non-Small Cell Lung Cancer
NCT05635708Non-small Cell Lung Cancer, Metastatic Non-small Cell Lung Cancer
DrugsGimistotug·Alcestobart·Nab-paclitaxel·Pemetrexed
BeiGene
Phase 2
400
California, Massachusetts, New York, Oregon, Texas
2023-03-07
Active, closed
A Study Evaluating AB248 Alone or in Combination With Pembrolizumab in Adult Patients With Solid Tumors
NCT05653882Solid Tumor, Non Small Cell Lung Cancer, Melanoma, Squamous Cell Carcinoma of Head and Neck
DrugsEtakafusp alfa·Keytruda·Pembrolizumab
Asher Biotherapeutics, Inc.
Phase 1
552
California, Connecticut, Florida, Illinois, Massachusetts, Michigan, Missouri, New Jersey
2023-01-04
Active, closed
A Study of YL202 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer and Breast Cancer
NCT05653752Non Small Cell Lung Cancer, Breast Cancer
DrugYL202
MediLink Therapeutics (Suzhou) Co., Ltd.
Phase 1
80
Florida, Michigan, Texas, Virginia, Washington
2022-12-20
Active, closed
A Study of DZD9008 Versus Platinum-Based Doublet Chemotherapy in Local Advanced or Metastatic Non-small Cell Lung Cancer (WU-KONG28)
NCT05668988Non-small Cell Lung Cancer
DrugsSunvozertinib·Pemetrexed·Carboplatin
Dizal Pharmaceuticals
Phase 3
324
California, Colorado, Florida, New York, Ohio, Oregon, Texas, Virginia
2022-12-13
Active, closed
A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors
NCT05538130Melanoma, Glioma, Thyroid Cancer, Non-Small Cell Lung Cancer
DrugPF-07799933
Pfizer
Phase 1
148
Alabama, Arkansas, California, Florida, Louisiana, Massachusetts, Michigan, New Jersey
2022-11-30
Active, closed
Study of the Monoclonal Antibody IMT-009 in Patients With Advanced Solid Tumors or Lymphomas
NCT05565417Non Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Triple Negative Breast Cancer, Cutaneous Squamous Cell Carcinoma
Immunitas Therapeutics
Phase 1/2
67
Arizona, Colorado, Florida, Oklahoma, Oregon, Tennessee, Texas, Virginia
2022-11-28
Recruiting
Predicting Responsiveness in Oncology Patients Based on Host Response Evaluation During Anti Cancer Treatments, Using Multiomics
NCT05736029Non Small Cell Lung Cancer, Healthy
OncoHost Ltd.
Observational
350
Texas
2022-11-07
Active, closed
A Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of Participants With Locally Advanced, Unresectable, Stage III Non-Small Cell Lung Cancer (NSCLC)
NCT05170204Non-Small Cell Lung Cancer
DrugsEntrectinib·Alectinib·Durvalumab
Hoffmann-La Roche
Phase 3
68
Oregon, Pennsylvania
2022-11-01
Active, closed
Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation
NCT05358249KRAS G12C Mutant Solid Tumors, Carcinoma, Non-Small Cell Lung, Carcinoma, Non-Small-Cell Lung, Non-Small Cell Lung Cancer
DrugsOpnurasib·Trametinib·Ribociclib·Cetuximab
Novartis Pharmaceuticals
Phase 1/2
74
Massachusetts, New York
2022-10-24
Active, closed
Zimberelimab and Domvanalimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy in Patients With Untreated Metastatic Non-Small Cell Lung Cancer
NCT05502237Non-small Cell Lung Cancer
DrugsDomvanalimab·Zimberelimab·Nab-paclitaxel·Pemetrexed
Gilead Sciences
Phase 3
1,021
California, District of Columbia, Florida, Illinois, North Carolina, Ohio, Oregon, Pennsylvania
2022-10-12
Recruiting
Study to Evaluate Sutetinib Maleate Capsule in Locally Advanced or Metastatic Non-small Cell Lung Cancer
NCT05168566Non-small Cell Lung Cancer
DrugSutetinib Maleate
Teligene US
Phase 2
99
California, Georgia, Kentucky, Maryland, North Carolina, Texas
2022-09-01
Recruiting
Blood-brain Barrier (BBB) Opening Using Exablate Focused Ultrasound With Standard of Care Treatment of NSCLC Brain Mets
NCT05317858Brain Tumor, Non Small Cell Lung Cancer
DrugsCemiplimab·Tecentriq·Atezolizumab·Nivolumab
InSightec
Phase 3
30
Arizona, California, Florida, Maryland, North Carolina, Oregon, Rhode Island, Virginia
2022-08-12
Recruiting
Dose Escalation/Expansion Study of Mavrostobart (PT199), an Anti-CD73 mAb, Administered Alone and in Combination With a PD-1 Inhibitor or Chemotherapy (the MORNINGSTAR Study)
NCT05431270Non Small Cell Lung Cancer, Pancreatic Ductal Adenocarcinoma
DrugsNab-paclitaxel·Pemetrexed·Tislelizumab·Docetaxel
Phanes Therapeutics
Phase 1/2
40
North Carolina, Oklahoma, Tennessee, Texas, Virginia
2022-08-11
Active, closed
A Dose Escalation Study of HBI-2438 in Patients With Solid Tumors Harboring KRAS G12C Mutation
NCT05485974Lung Cancer, Non Small Cell Lung Cancer, Colorectal Cancer, Cancer of Pancreas
HUYABIO International, LLC.
Phase 1
44
California, Florida, Michigan, Missouri, Ohio
2022-08-01
Active, closed
A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations.
NCT05355701Melanoma, Non-Small-Cell Lung Cancer, Thyroid Cancer, Glioma
DrugsPF-07799933·Binimetinib·Erbitux·Midazolam
Pfizer
Phase 1
103
Arkansas, Colorado, Florida, Massachusetts, Michigan, New Jersey, New York, Ohio
2022-07-05
Recruiting
GEMINI-NSCLC: NSCLC Biomarker Study
NCT05236114Non-Small Cell Lung Cancer
Tempus AI
Observational
1,200
Alabama, Arkansas, California, Connecticut, Florida, Georgia, Hawaii, Illinois
2022-06-22
Recruiting
Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer
NCT05142189Non-Small Cell Lung Cancer
DrugsBNT116·Gotistobart·Cemiplimab·Osimertinib
BioNTech SE
Phase 1
320
Kentucky, Maryland, Ohio, Texas, Virginia
2022-06-17
Active, closed
Study of JDQ443 in Comparison With Docetaxel in Participants With Locally Advanced or Metastatic KRAS G12C Mutant Non-small Cell Lung Cancer
NCT05132075Non-Small Cell Lung Cancer
DrugsOpnurasib·Docetaxel
Novartis Pharmaceuticals
Phase 3
95
Washington
2022-06-15
Recruiting
Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion
NCT05245500Mesothelioma, Non Small Cell Lung Cancer, Malignant Peripheral Nerve Sheath Tumors, Solid Tumor
DrugNavlimetostat
Bristol-Myers Squibb
Phase 1
336
Arizona, Colorado, Florida, Illinois, Massachusetts, Michigan, Minnesota, New Jersey
2022-06-09
Active, closed
Study of Sacituzumab Govitecan Combinations in First-line Treatment of Participants With Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC)
NCT05186974Non-small Cell Lung Cancer
DrugsSacituzumab Govitecan·Paraplatin·Keytruda·Cisplatin
Gilead Sciences
Phase 2
193
Alaska, California, Colorado, District of Columbia, Florida, Georgia, Illinois, Kansas
2022-05-30
Recruiting
MEM-288 Oncolytic Virus Alone and in Combination With Standard of Care Therapy in Advanced Solid Tumors
NCT05076760Solid Tumor, Advanced Cancer, Metastatic Cancer, Non Small Cell Lung Cancer
DrugsOpdivo·Docetaxel·Nivolumab
Memgen, Inc.
Phase 1
40
Florida, North Carolina
2022-04-21
Recruiting
Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer
NCT05061550Non-small Cell Lung Cancer
DrugsAZD0171·Pemetrexed/Cisplatin·Pemetrexed/Carboplatin·Monalizumab
AstraZeneca
Phase 2
630
Arkansas, California, Connecticut, Florida, Georgia, Illinois, Maryland, Massachusetts
2022-04-14
Active, closed
Phase 1/2 Study of Avutometinib (VS-6766) + Sotorasib With or Without Defactinib in KRAS G12C NSCLC Patients
NCT05074810Non Small Cell Lung Cancer, KRAS Activating Mutation
DrugLumakras
Verastem, Inc.
Phase 1/2
153
Colorado, District of Columbia, Illinois, Maryland, Massachusetts, Michigan, Minnesota, Missouri
2022-04-12
Recruiting
Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer
NCT05267626Advanced Solid Tumor, Metastatic Cancer, Cutaneous Melanoma, Non-Small Cell Lung Cancer
DrugsAvelumab·Aldesleukin·Nivolumab
Aulos Bioscience, Inc.
Phase 1/2
159
Florida, Michigan, Minnesota, Missouri, North Carolina, Tennessee, Texas, Utah
2022-04-04
Active, closed
Study of NGM831 as Monotherapy and in Combination With Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors
NCT05215574Pancreatic Cancer, Breast Cancer, Gastric Cancer, Non-small Cell Lung Cancer
DrugsKeytruda·Pembrolizumab
NGM Biopharmaceuticals, Inc
Phase 1
130
Arizona, California, Florida, Michigan, New York, Oklahoma, Texas
2022-03-31
Active, closed
Phase 1/2 Study of Silevertinib (BDTX-1535) in Patients With Glioblastoma or Non-Small Cell Lung Cancer With EGFR Mutations
NCT05256290Non-Small Cell Lung Cancer, Advanced Non-Small Cell Squamous Lung Cancer, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Lung Cancer
Black Diamond Therapeutics, Inc.
Phase 1/2
200
Alabama, Arizona, California, District of Columbia, Florida, Hawaii, Illinois, Kansas
2022-03-31
Recruiting
A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
NCT04928846Non Small Cell Lung Cancer, c-MET
DrugsTelisotuzumab vedotin·Docetaxel
AbbVie
Phase 3
768
Alabama, Arizona, California, Florida, Georgia, Hawaii, Illinois, Indiana
2022-03-25
Active, closed
A Global Study to Assess the Effects of Osimertinib in Participants With EGFRm Stage IA2-IA3 NSCLC Following Complete Tumour Resection
NCT05120349Non-Small Cell Lung Cancer
DrugsTagrisso·Osimertinib
AstraZeneca
Phase 3
390
Alaska, California, Colorado, Delaware, Georgia, Illinois, Maryland, New Jersey
2022-02-21
Active, closed
A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants With Stage III Unresectable NSCLC
NCT05211895Non-Small Cell Lung Cancer
DrugsDomvanalimab·Durvalumab
AstraZeneca
Phase 3
791
Arizona, California, District of Columbia, Florida, Georgia, Illinois, Kentucky, Maryland
2022-02-18
Active, closed
P-MUC1C-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Advanced or Metastatic Solid Tumors
NCT05239143Breast Cancer, Ovarian Cancer, Non Small Cell Lung Cancer, Colorectal Cancer
DrugRimiducid
Poseida Therapeutics, Inc.
Phase 1
180
California, Colorado, Iowa, Kansas, Maryland, Massachusetts, Nebraska, New York
2022-02-15
Recruiting
First in Human Phase 1 Study of AG01 Anti-Progranulin/GP88 Antibody in Advanced Solid Tumor Malignancies
NCT05627960Triple Negative Breast Cancer, Hormone-Resistant Breast Cancer, Non Small Cell Lung Cancer, Mesothelioma
A&G Pharmaceutical Inc.
Phase 1
77
Maryland
2022-02-14
Active, closed
A Global Study to Assess the Effects of Durvalumab With Oleclumab or Durvalumab With Monalizumab Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer
NCT05221840Non-Small Cell Lung Cancer
DrugsMonalizumab·Oleclumab·Durvalumab
AstraZeneca
Phase 3
1,051
California, Connecticut, Florida, Illinois, Indiana, Kentucky, Maryland, Michigan
2022-02-07
Recruiting
Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers
NCT05098132Advanced Solid Tumor, Non Small Cell Lung Cancer, Untreated Advanced NSCLC, 1st Line NSCLC
DrugsPembrolizumab KEYTRUDA·Pemetrexed·Carboplatin
Synthekine
Phase 1/2
364
Arizona, California, Connecticut, District of Columbia, Georgia, Illinois, Maryland, Massachusetts
2022-01-25
Active, closed
Lorlatinib Continuation Study
NCT05144997Non-Small-Cell Lung Cancer, NSCLC
DrugLorlatinib
Pfizer
Phase 4
76
California
2021-12-28
Active, closed
A Dose Escalation Study of SHP2 Inhibitor in Patients With Solid Tumors Harboring KRAS of EGFR Mutations
NCT05163028Non Small Cell Lung Cancer, Colorectal Cancer, Pancreatic Cancer, Solid Tumor
HUYABIO International, LLC.
Phase 1
42
California, Florida, Ohio, Texas, Virginia
2021-12-13
Active, closed
MRD Assay Evaluates Recurrence and Response Via a Tumor Informed Assessment
NCT05219734Cancer, Solid Tumor, Non Small Cell Lung Cancer, Colorectal Cancer
Invitae Corporation
Observational
400
Indiana, North Carolina
2021-11-29
Active, closed
Study of Sacituzumab Govitecan (SG) Versus Docetaxel in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
NCT05089734Non-Small Cell Lung Cancer
DrugsSacituzumab Govitecan·Docetaxel
Gilead Sciences
Phase 3
603
Alaska, Arizona, California, Colorado, Florida, Illinois, Iowa, Kansas
2021-11-17
Active, closed
A Study of NDI 1150-101 in Patients With Solid Tumors
NCT05128487Solid Tumor, Renal Cell Carcinoma (Kidney Cancer), Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma, Non-Small Cell Lung Cancer
DrugPembrolizumab
Nimbus Saturn, Inc.
Phase 1/2
106
Arizona, Connecticut, District of Columbia, Florida, Kentucky, Maryland, Michigan, Minnesota
2021-11-05
Recruiting
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan
NCT05005403Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Micro Satellite Stable Colorectal Cancer, Gastric/Esophageal Cancer
DrugsBudigalimab·Telisotuzumab Adizutecan·Bevacizumab
AbbVie
Phase 1
694
California, Illinois, Indiana, Kentucky, Michigan, Minnesota, Nebraska, North Carolina
2021-11-01
Recruiting
Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
NCT04981119Solid Tumor, Adult, Colorectal Cancer, Non Small Cell Lung Cancer, Pancreatic Cancer
A2 Biotherapeutics Inc.
Observational
500
Arizona, California, Florida, Massachusetts, Minnesota, Missouri, New York, Ohio
2021-10-29
Active, closed
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 as Monotherapy and in Combination With IV Bevacizumab
NCT05029882Non-Small Cell Lung Cancer, Advanced Solid Tumors, Gastroesophageal Adenocarcinoma, Colorectal Cancer
DrugsTelisotuzumab Adizutecan·Trifluridine/Tipiracil·Bevacizumab
AbbVie
Phase 1
520
California, Colorado, Connecticut, Illinois, Indiana, Louisiana, Michigan, New York
2021-10-13
Active, closed
A Study to Evaluate Chemotherapy Plus Osimertinib Against Chemotherapy Plus Placebo in Patients With Non-small Cell Lung Cancer (NSCLC)
NCT04765059Non-small Cell Lung Cancer
DrugCarboplatin
AstraZeneca
Phase 3
98
Maryland, Massachusetts
2021-09-12
Recruiting
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
NCT05059444Bladder Carcinoma, Ureter Carcinoma, Renal Pelvis Carcinoma, Non-small Cell Lung Cancer
Guardant Health, Inc.
Observational
2,285
Alabama, Arizona, Arkansas, California, Colorado, Florida, Louisiana, Maine
2021-09-07
Active, closed
Taletrectinib Phase 2 Global Study in ROS1 Positive NSCLC
NCT04919811Non Small Cell Lung Cancer
DrugTaletrectinib
Nuvation Bio Inc.
Phase 2
217
California, Florida, Louisiana, Minnesota, New Jersey, Ohio, Tennessee, Texas
2021-09-01
Active, closed
Study of Pembrolizumab (MK-3475) Subcutaneous (SC) Versus Pembrolizumab Intravenous (IV) Administered With Platinum Doublet Chemotherapy in Participants With Metastatic Squamous or Nonsquamous Non-Small Cell Lung Cancer (NSCLC) (MK-3475-A86)
NCT04956692Non-Small Cell Lung Cancer
DrugsAbraxane·Paraplatin·Taxol·Nab-paclitaxel
Merck Sharp & Dohme LLC
Phase 3
531
Arkansas, California, Florida, Indiana, Kentucky, Missouri, Montana, New York
2021-08-05
Recruiting
A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors
NCT04913285Solid Tumor, Adult, Non-small Cell Lung Cancer, Melanoma
Pierre Fabre Medicament
Phase 1
400
California, Colorado, Florida, Minnesota, New Jersey, New York, Ohio, Tennessee
2021-08-04
Active, closed
Beamion LUNG-1: A Study to Test Different Doses of Zongertinib in People With Different Types of Advanced Cancer (Solid Tumours With Changes in the HER2 Gene)
NCT04886804Neoplasm Metastasis, Non-Small Cell Lung Cancer
DrugZongertinib
Boehringer Ingelheim
Phase 1
554
Alabama, California, District of Columbia, Florida, Georgia, Hawaii, New York, North Carolina
2021-07-02
Recruiting
A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors
NCT04895709Cervical Cancer, Gastric/Gastroesophageal Junction Adenocarcinoma, Microsatellite Stable Colorectal Cancer, Non-Small-Cell Lung Cancer
DrugsImzokitug·Pumitamig·Docetaxel·Nivolumab
Bristol-Myers Squibb
Phase 1/2
1,109
California, Iowa, New Jersey, New York, Oregon, Tennessee, Texas
2021-05-27
Active, closed
Study Evaluating Effectiveness and Safety of Zimberelimab and Domvanalimab in Lung Cancer
NCT04736173Non Small Cell Lung Cancer, Nonsquamous Non Small Cell Lung Cancer, Squamous Non Small Cell Lung Cancer, Lung Cancer
DrugsDomvanalimab·Zimberelimab·Pemetrexed·Paclitaxel
Arcus Biosciences, Inc.
Phase 2
169
Georgia, Texas, Virginia
2021-02-08
Active, closed
Study of DS-1062a Versus Docetaxel in Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer With or Without Actionable Genomic Alterations (TROPION-LUNG01)
NCT04656652Non-small Cell Lung Cancer
DrugsDato-DXd·Docetaxel
Daiichi Sankyo
Phase 3
605
Arizona, California, Florida, Illinois, Indiana, Kentucky, Louisiana, Maryland
2020-12-21
Active, closed
A Study of Osimertinib With or Without Chemotherapy Versus Chemotherapy Alone as Neoadjuvant Therapy for Patients With EGFRm Positive Resectable Non-Small Cell Lung Cancer
NCT04351555Non-Small Cell Lung Cancer
DrugsTagrisso·Osimertinib·Pemetrexed·Cisplatin
AstraZeneca
Phase 3
358
California, Massachusetts, New Hampshire, New York, Texas, Virginia, Washington
2020-12-16
Recruiting
A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)
NCT04302025Non-small Cell Lung Cancer
DrugsCobimetinib·Pralsetinib·Divarasib·SBRT
Genentech, Inc.
Phase 2
99
California, Colorado, Connecticut, District of Columbia, Florida, Illinois, Massachusetts, Michigan
2020-11-06
Active, closed
CAN-2409 Plus Prodrug With Standard of Care Immune Checkpoint Inhibitor for Stage III/IV NSCLC
NCT04495153Non Small Cell Lung Cancer
DrugAglatimagene besadenovec
Candel Therapeutics, Inc.
Phase 2
90
Arizona, Connecticut, Illinois, Maryland, Minnesota, New York, Ohio, Pennsylvania
2020-10-13
Active, closed
A Study of DSP107 Alone and in Combination with Atezolizumab for Patients with Advanced Solid Tumors
NCT04440735Advanced Solid Tumor, Non Small Cell Lung Cancer, Colorectal Cancer
DrugsDSP107·Atezolizumab
Kahr Medical
Phase 1/2
125
California, Colorado, Florida, Indiana, Kansas, Pennsylvania
2020-10-07
Active, closed
A Study Comparing Savolitinib Plus Osimertinib vs Savolitinib Plus Placebo in Patients With EGFRm+ and MET Amplified Advanced NSCLC
NCT04606771Non-Small Cell Lung Cancer
DrugsSavolitinib·Osimertinib
AstraZeneca
Phase 2
30
California
2020-09-28
Active, closed
Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC
NCT04140526Non Small Cell Lung Cancer, Advanced Solid Tumor, Metastatic Melanoma, Metastatic Head and Neck Carcinoma
DrugsGotistobart·Taxotere·Docetaxel·Keytruda
OncoC4, Inc.
Phase 1/2
733
Arkansas, California, Colorado, Connecticut, District of Columbia, Florida, Georgia, Kentucky
2020-09-16
Active, closed
Adjuvant Chemotherapy in Patients With Intermediate or High Risk Stage I or Stage IIA Non-squamous Non-Small Cell Lung Cancer: AIM-HIGH (Adjuvant Intervention in Molecular High Risk Patients)
NCT01817192Non-Small Cell Lung Cancer
Razor Genomics
Not applicable
420
California, Florida, Kentucky, Missouri, New Jersey, North Carolina, Oklahoma, Pennsylvania
2020-09-11
Active, closed
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-6036 Alone or in Combination in Participants With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation
NCT04449874Non-Small Cell Lung Cancer, Colorectal Cancer, Advanced Solid Tumors
DrugsDivarasib·Erlotinib·Inavolisib·Cetuximab
Genentech, Inc.
Phase 1
498
California, Connecticut, Florida, Massachusetts, New York, Oklahoma, Pennsylvania
2020-07-29
Recruiting
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
NCT04198766Solid Tumor, Non-Small Cell Lung Cancer, Head and Neck Cancer, Melanoma
DrugsCarboplatin (AUC 5)·Carboplatin (AUC 6)·Nab-paclitaxel·Pemetrexed
Inhibrx Biosciences, Inc
Phase 1/2
340
California, Florida, Georgia, Illinois, Iowa, Kentucky, Michigan, Minnesota
2019-12-10
Active, closed
Study BT5528-100 in Patients With Advanced Solid Tumors Associated With EphA2 Expression
NCT04180371Advanced Solid Tumor Historically Known for High EphA2 Expression, Urothelial Cancer, Ovarian Cancer, Non-small Cell Lung Cancer
DrugsNuzefatide pevedotin·Opdivo·Nivolumab
BicycleTx Limited
Phase 1/2
288
California, Colorado, Florida, Michigan, Nevada, New York, Oklahoma, Pennsylvania
2019-11-07
Active, closed
A Phase 1/2 Trial of CLN-081 in Patients With Non-Small Cell Lung Cancer
NCT04036682Non Small Cell Lung Cancer, EGFR Exon 20 Mutation
DrugZipalertinib
Cullinan Therapeutics Inc.
Phase 1/2
284
California, Florida, Massachusetts, Michigan, New Jersey, New York, Ohio, Oregon
2019-10-31
Active, closed
Neoadjuvant Cemiplimab for the Treatment of Resectable NSCLC, HCC, and HNSCC in Adult Patients
NCT03916627Non-small Cell Lung Cancer, Hepatocellular Carcinoma, Head and Neck Squamous Cell Carcinoma
DrugsFianlimab·Cemiplimab
Regeneron Pharmaceuticals
Phase 2
65
New York
2019-07-23
Active, closed
Assessing an Oral EGFR Inhibitor, Sunvozertinib in Patients Who Have Advanced Non-small Cell Lung Cancer With EGFR or HER2 Mutation (WU-KONG1)
NCT03974022Non-Small Cell Lung Cancer
DrugSunvozertinib
Dizal Pharmaceuticals
Phase 1/2
315
California, Colorado, Florida, Massachusetts, Michigan, New York, Ohio, Virginia
2019-07-09
Active, closed
A Study of Osimertinib With or Without Chemotherapy as 1st Line Treatment in Patients With Mutated Epidermal Growth Factor Receptor Non-Small Cell Lung Cancer (FLAURA2)
NCT04035486Non-Small Cell Lung Cancer
DrugsPemetrexed/Cisplatin·Pemetrexed/Carboplatin·Osimertinib
AstraZeneca
Phase 3
587
California, Florida, Kansas, Kentucky, Massachusetts, Nevada, New York, Ohio
2019-07-02
Active, closed
Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy (ORCHARD)
NCT03944772Non-Small Cell Lung Cancer
DrugsNecitumumab·Gefitinib·Savolitinib·Selpercatinib
AstraZeneca
Phase 2
247
California, Connecticut, Illinois, Maryland, Massachusetts, Michigan, New York, Oregon
2019-06-25
Active, closed
Ph I/II Trial of Systemic VSV-IFNβ-NIS in Combination With Checkpoint Inhibitor Therapy in Patients With Select Solid Tumors
NCT03647163Solid Tumor, Non Small Cell Lung Cancer, Neuroendocrine Carcinoma, Renal Cell Carcinoma (RCC)
DrugsVSV-IFNβ-NIS·Ipilimumab·Nivolumab·Pembrolizumab
Vyriad, Inc.
Phase 1/2
33
Minnesota, Ohio
2019-04-09
Active, closed
Study of NEO-201 in Solid Tumors Expansion Cohorts
NCT03476681Non Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Cervical Cancer, Uterine Cancer
DrugPembrolizumab
Precision Biologics, Inc
Phase 1/2
121
Maryland, Virginia
2019-01-18
Active, closed
Study of an Immunotherapeutic, DPX-Survivac, in Combination With Low Dose Cyclophosphamide & Pembrolizumab, in Subjects With Selected Advanced & Recurrent Solid Tumors
NCT03836352Ovarian Cancer, Hepatocellular Carcinoma, Non-small Cell Lung Cancer, Bladder Cancer
DrugsCyclophosphamide·Pembrolizumab
ImmunoVaccine Technologies, Inc. (IMV Inc.)
Phase 2
184
Arizona, California, Florida, Georgia, Kentucky, Louisiana, Minnesota, New Mexico
2018-12-21
Active, closed
QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors
NCT03228667Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Urothelial Carcinoma, Head and Neck Squamous Cell Carcinoma
DrugsPD-L1 t-haNK·Avelumab·Atezolizumab·Durvalumab
ImmunityBio, Inc.
Phase 2
40
Alaska, Arkansas, California, Florida, Indiana, Iowa, Kentucky, Massachusetts
2018-12-11
Active, closed
A Study of Neoadjuvant/Adjuvant Durvalumab for the Treatment of Patients With Resectable Non-small Cell Lung Cancer
NCT03800134Non-Small Cell Lung Cancer
DrugsDurvalumab·Pemetrexed·Gemcitabine·Paclitaxel
AstraZeneca
Phase 3
825
Arizona, California, Colorado, Florida, Illinois, Kansas, Kentucky, Maryland
2018-12-06
Active, closed
Study of Telisotuzumab Vedotin (ABBV-399) in Participants With Previously Treated c-Met+ Non-Small Cell Lung Cancer
NCT03539536Non-small Cell Lung Cancer
DrugTelisotuzumab vedotin
AbbVie
Phase 2
270
Alabama, Arizona, Arkansas, California, Colorado, Florida, Hawaii, Illinois
2018-10-10
Recruiting
VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma
NCT03556228Head and Neck Carcinoma, Adenoid Cystic Carcinoma, Lung Cancer, Non-Small Cell Lung Cancer
VM Oncology, LLC
Phase 1/2
242
California, Connecticut, District of Columbia, Florida, New Jersey, New Mexico, New York, Ohio
2018-06-08
Active, closed
Efficacy and Safety of Pembrolizumab (MK-3475) With Platinum Doublet Chemotherapy as Neoadjuvant/Adjuvant Therapy for Participants With Resectable Stage II, IIIA, and Resectable IIIB (T3-4N2) Non-small Cell Lung Cancer (MK-3475-671/KEYNOTE-671)
NCT03425643Non-small Cell Lung Cancer
DrugsPemetrexed·Keytruda·Gemcitabine·Cisplatin
Merck Sharp & Dohme LLC
Phase 3
797
Arizona, California, Connecticut, Delaware, Florida, Georgia, Illinois, Indiana
2018-04-24
Active, closed
First-in-human Study of DS-1062a for Advanced Solid Tumors (TROPION-PanTumor01)
NCT03401385Hormone Receptor Positive Breast Cancer, Triple Negative Breast Cancer, Non-small Cell Lung Cancer
DrugDato-DXd
Daiichi Sankyo Co., Ltd.
Phase 1
890
California, District of Columbia, Georgia, Maryland, Massachusetts, New York, Tennessee, Texas
2018-01-31
Recruiting
Dabrafenib and/or Trametinib Rollover Study
NCT03340506Melanoma, Non Small Cell Lung Cancer, Solid Tumor, Rare Cancers
DrugsDabrafenib·Trametinib
Novartis Pharmaceuticals
Phase 4
100
Arizona, Maryland, Ohio, Texas
2018-01-26
Active, closed
Phase II Umbrella Study of Novel Anti-cancer Agents in Participants With NSCLC Who Progressed on an Anti-PD-1/PD-L1 Containing Therapy
NCT03334617Non-Small Cell Lung Cancer
DrugsDanvatirsen·Vistusertib·Cediranib Maleate·Ceralasertib
AstraZeneca
Phase 2
528
California, District of Columbia, Illinois, Maryland, Massachusetts, Missouri, New York, Pennsylvania
2017-12-18
Active, closed
A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC)
NCT03178552Non-Small Cell Lung Cancer
DrugsCobimetinib·Divarasib·Vemurafenib·Entrectinib
Hoffmann-La Roche
Phase 2/3
1,000
California, Colorado, Florida, Kentucky, Nevada, New Hampshire, New York, Oregon
2017-09-22
Active, closed
Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
NCT03170960Urothelial Carcinoma, Renal Cell Carcinoma, Non-Small Cell Lung Cancer, Castration-resistant Prostate Cancer
DrugsCabozantinib·Tecentriq·Atezolizumab
Exelixis
Phase 1
914
Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Georgia, Illinois
2017-09-05
Active, closed
A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001)
NCT03157128Non-Small Cell Lung Cancer, Medullary Thyroid Cancer, Colon Cancer, Any Solid Tumor
DrugSelpercatinib
Eli Lilly and Company
Phase 1/2
857
Arizona, California, Colorado, Connecticut, Florida, Georgia, Illinois, Louisiana
2017-05-02
Active, closed
A Study of Abemaciclib (LY2835219) in Participants With Non-Small Cell Lung Cancer or Breast Cancer
NCT02779751Non Small Cell Lung Cancer, Breast Cancer
DrugsAnastrozole·Abemaciclib·Pembrolizumab
Eli Lilly and Company
Phase 1
100
Arkansas, California, Colorado, Massachusetts, Michigan, New York
2016-11-14
Active, closed
eXalt3: Study Comparing X-396 (Ensartinib) to Crizotinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) Patients
NCT02767804Non-small Cell Lung Cancer
DrugsEnsartinib·Crizotinib
Xcovery Holdings, Inc.
Phase 3
290
Florida, Georgia, Missouri, Oregon
2016-06
Active, closed
Study of Amivantamab, a Human Bispecific EGFR and cMet Antibody, in Participants With Advanced Non-Small Cell Lung Cancer
NCT02609776Non-Small-Cell Lung Cancer
DrugsLazertinib·Amivantamab·Pemetrexed·Carboplatin
Janssen Research & Development, LLC
Phase 1
751
California, Florida, Illinois, Maryland, Massachusetts, Michigan, Minnesota, Missouri
2016-05-24
Active, closed
Clinical Effectiveness Assessment of VeriStrat® Testing and Validation of Immunotherapy Tests in NSCLC Subjects
NCT03289780Non-Small Cell Lung Cancer
Biodesix, Inc.
Observational
5,006
Alabama, Arkansas, California, Connecticut, Florida, Georgia, Illinois, Indiana
2016-04-04
Active, closed
A Study of Abemaciclib (LY2835219) in Participants With Previously Treated KRAS Mutated Lung Cancer
NCT02152631Non Small Cell Lung Cancer
DrugsErlotinib·Abemaciclib
Eli Lilly and Company
Phase 3
453
Arkansas, California, Colorado, Delaware, Florida, Georgia, Illinois, Indiana
2014-10-03
Rows per page Showing 1–190 of 190
1
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a US investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 6 October 2026. https://priyalifescience.com/clinical-trials-usa/condition/non-small-cell-lung-cancer

Query this register directly
GET /api/trials?country=usa&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every industry-sponsored study on the registry that lists at least one investigative site in the US and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 9,118 studies in total at the last sync on 06 Oct 2026, 03:16 UTC. Academic and other non-industry sponsors are out of scope by design. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 190 of those studies listing the condition Non-Small Cell Lung Cancer.

How many Non-Small Cell Lung Cancer trials are recruiting in the US?

99 of the 190 studies on this page are recruiting new participants as of the 06 Oct 2026, 03:16 UTC sync. A further 7 have not yet opened recruitment, 83 are active but closed to new participants, and 1 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Non-Small Cell Lung Cancer), 190 studies
PhaseStudiesRecruitingShare
Phase 1522727.4%
Phase 3472424.7%
Phase 1/2382020%
Phase 2331517.4%
Observational1185.8%
Phase 2/3643.2%
Phase 4211.1%
Not applicable100.5%

Most active sponsors

Lead sponsors with the most studies (Non-Small Cell Lung Cancer)
Lead sponsorStudiesRecruiting
AstraZeneca228
Merck Sharp & Dohme LLC127
AbbVie75
Bristol-Myers Squibb64
Eli Lilly and Company62
Hoffmann-La Roche63
Pfizer63
Gilead Sciences51
BioNTech SE44
Novartis Pharmaceuticals42

Top states

Top states (Non-Small Cell Lung Cancer), by number of studies with a site there
StateStudies
California140
Florida114
Illinois72
New York63
Texas53
Massachusetts48
Colorado47
Georgia47
Michigan46
Connecticut43
Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the US Pharma Salary Guide, see who's behind them in the US Company Directory, or track approvals on the FDA Approvals Tracker. For Irish, UK and EU sites, see the Ireland, UK and EU registers.